pharmaphorum
SEPTEMBER 10, 2020
The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. subtilis spores engineered to present SARS-CoV-2 antigens to the mucosal immune system.
pharmaphorum
DECEMBER 9, 2020
Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. of participants. of participants.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 20, 2022
Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease.
PharmaShots
FEBRUARY 28, 2023
The signs and symptoms of a potential vaccine injury can vary. Other adverse reactions that could be attributed to a vaccine injury include neurological disorders such as seizures, autoimmune diseases, and allergic reactions. Read on to learn more about vaccine injuries and their symptoms.
European Pharmaceutical Review
DECEMBER 19, 2022
Treatment and care of patients with high-risk NMIBC, including those with CIS often involves removing the tumour and the use of the BCG vaccine to reduce the risk that the cancer will recur. The FDA stated that individuals who are immunosuppressed, or immune-deficient should not come into contact with Adstiladrin.
Pharmaceutical Technology
MAY 15, 2023
A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome. OVs can be attenuated natural viruses or recombinant viruses.
pharmaphorum
JULY 5, 2021
Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. While these numbers do tell us something about the relative immunity of the population writ large, they don’t tell us anything about our own, personal immune profiles. However, we’ve also found a number of outliers.
Expert insights. Personalized for you.
133 
Let's personalize your content